Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Stoke Therapeutics Inc shares valued at $52,379 were sold by Ticho Barry on Jul 01 ’25. At $11.63 per share, Ticho Barry sold 4,503 shares. The insider’s holdings dropped to 21,279 shares worth approximately $0.26 million following the completion of this transaction.
Also, BARUCH TICHO purchased 9,007 shares, netting a total of over 102,229 in proceeds.
Before that, Skorpios Trust had sold 3,000,000 shares from its account. In a trade valued at $30,600,000, the 10% Owner traded Stoke Therapeutics Inc shares for $10.20 each. Upon closing the transaction, the insider’s holdings decreased to 3,000,000 shares, worth approximately $46.95 million.
As published in their initiating research note from Chardan Capital Markets on December 20, 2024, Stoke Therapeutics Inc [STOK] has been a Buy and the price target has been revised to $24. As of March 26, 2024, TD Cowen has increased its “Market perform” rating to a “an Outperform” for STOK.
Analyzing STOK Stock Performance
On last trading session,, Stoke Therapeutics Inc [NASDAQ: STOK] rose 0.08% to $12.02. The stock’s lowest price that day was $11.9, but it reached a high of $12.455 in the same session. During the last five days, there has been a surge of approximately 3.18%. Over the course of the year, Stoke Therapeutics Inc shares have dropped approximately -8.38%. Shares of the company reached a 52-week high of $12.98 on 02/05/25 and a 52-week low of $5.35 on 04/09/25.
Support And Resistance Levels for Stoke Therapeutics Inc (STOK)
According to the 24-hour chart, there is a support level at 11.80, which, if violated, would cause prices to drop to 11.57. In the upper region, resistance lies at 12.35. The next price resistance is at 12.68. RSI (Relative Strength Index) is 65.97 on the 14-day chart, showing neutral technical sentiment.
Is Stoke Therapeutics Inc subject to short interest?
Stocks of Stoke Therapeutics Inc saw a sharp rise in short interest on 2025-06-13 jumping by 0.43 million shares to 12.11 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 11.67 million shares. A jump of 3.58% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 20.21 of the overall float, the days-to-cover ratio (short ratio) jumped to 20.21.
Which companies own the most shares of Stoke Therapeutics Inc (STOK)?
In terms of Stoke Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 22 in the next 12 months, up nearly 83.18% from the previous closing price of $12.01. Analysts anticipate Stoke Therapeutics Inc stock to reach 58 by 2025, with the lowest price target being 18. In spite of this, 5 analysts ranked Stoke Therapeutics Inc stock as Buy at the end of 2025.
